Bill > S1532

This bill requires the Government Accountability Office (GAO) to study the role of Pharmacy Benefit Managers (PBMs) in the pharmaceutical supply chain and provide Congress with policy recommendations. The study will address the state of competition among the top 10 PBMs, their use of drug rebates and fees, whether PBM formularies favor high-rebate drugs, the average prior authorization approval time, factors affecting step therapy, and the extent to which PBMs charge payors more than they pay pharmacies. The goal is to lower prescription drug costs for consumers and payors, improve the efficiency of the supply chain, enhance competition in PBM services, and increase transparency in PBM practices.